TY - JOUR T1 - From Delta to Omicron: analysing the SARS-CoV-2 epidemic in France using variant-specific screening tests (September 1 to December 18, 2021) JF - medRxiv DO - 10.1101/2021.12.31.21268583 SP - 2021.12.31.21268583 AU - Mircea T. Sofonea AU - Bénédicte Roquebert AU - Vincent Foulongne AU - Laura Verdurme AU - Sabine Trombert-Paolantoni AU - Mathilde Roussel AU - Stéphanie Haim-Boukobza AU - Samuel Alizon Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/01/2021.12.31.21268583.abstract N2 - We analysed 131,478 SARS-CoV-2 variant screening tests performed in France from September 1st to December 18, 2021. Tests consistent with the presence of the Omicron variant exhibit significantly higher cycle threshold Ct values, which could indicate lower amounts of virus genetic material. We estimate that the transmission advantage of the Omicron variant over the Delta variant is +105% (95% confidence interval: 96-114%). Based on these data, we use mechanistic mathematical modelling to explore scenarios for early 2022.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the Occitanie region and the ANR (PHYEPI grant).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Institutional Review Board of the CHU of Montpellier and is registered at ClinicalTrials.gov with identifier NCT04738331.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon publication and are available before that upon reasonable request to the authors. ER -